Image source: Getty Images.
Continue Reading Below
Shares of Momenta Pharmaceuticals (NASDAQ: MNTA)are up over 20% at 12:28 p.m. EST after the company announced that the U.S. District Court invalidated four of Teva Pharmaceutical's(NYSE: TEVA) patents on the three-times-weekly version of its multiple sclerosis drug Copaxone. Teva's shares are down 3% on the news.
Invalidating the patents moves Momenta and its partner Novartis (NYSE: NVS) one step closer to being able to sell their generic version of the drug, which they call Glatopa. The duo already sells a generic of the lower-dose daily version of Copaxone, but the three-times-weekly version is more popular. Teva Pharmaceutical has also been able to lock Momenta and Novartis out of some of the market by setting up deals with pharmacies that cover both drugs, so getting a generic version of the three-times-weekly version should also increase their penetration into the market for daily version.
There's still a patent on the three-times-weekly version of Copaxone that Mylan (NASDAQ: MYL), which is also developing a generic version of it, asked the Patent Trial and Appeal Board to review. A ruling on that patent should be released in April.
Teva Pharmaceutical said it plans to appeal the decision, so a final ruling on all the patents is likely a ways off. Nevertheless, Novartis and Momenta can still launch as soon as they receive Food and Drug Administration approval, but it would be an at-risk launch, subject to damages if Teva wins during the appeals process.
10 stocks we like better than Momenta Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Momenta Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of January 4, 2017